UBS Maintains Buy on Perspective Therapeutics, Lowers Price Target to $7

Perspective Therapeutics, Inc. -3.36% Post

Perspective Therapeutics, Inc.

CATX

5.17

5.17

-3.36%

0.00% Post
UBS analyst David Dai maintains Perspective Therapeutics (AMEX: CATX) with a Buy and lowers the price target from $18 to $7.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via